Investors, Strategics & Innovators

A HealthTech executive with over 20 years of experience in the areas of strategy, research, and product development. Catherine has a diverse background which covers surgery, medical technology, engineering, product design, healthcare, alternative energy, automotive, aerospace, global entrepreneurship, IP litigation, FDA compliance, education, and product development.

Bio coming soon.

Bernard J. Zovighian is CEO and on the Board of Directors of Edwards Lifesciences since May 2023, after serving as the company’s president. As CEO, Zovighian is leading Edwards into a new era of groundbreaking structural heart innovation, with a sharpened focus and pursuit of expanded opportunities to transform the care of structural heart patients worldwide. Building from Edwards’ foundation rooted in the company’s Credo, the patient-focused culture and the unique innovation strategy, Zovighian and the global Edwards employees are united and inspired to enable the company’s sustainable growth and extend its global leadership.

With a career spanning nearly three decades in medical technology, Zovighian has led global businesses across two world-class companies, during which time he lived and led teams in several countries. Zovighian blends a global mindset and a team-based approach to leadership with strengths in strategy development, innovation and adoption of disruptive technologies that elevate the standard of care, and establishment of trusted partnerships.

Zovighian joined Edwards Lifesciences in January 2015 as vice president and general manager of the Surgical Structural Heart business, and he later served as corporate vice president of the surgical business from 2016 until he became corporate vice president responsible for the company’s Transcatheter Mitral and Tricuspid Therapies (TMTT) business in January 2018. Zovighian established a global organization focused on developing a portfolio of therapies designed to change the standard of care for mitral and tricuspid patients. Prior to joining Edwards, Zovighian held roles with increasing levels of responsibility at Johnson & Johnson (J&J) for nearly 20 years, including worldwide president of one of the company’s divisions.

Currently, Zovighian serves as an advisory board member for the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California. He has dual master’s degrees in science and business from Universities of Marseille, France.

Bio coming soon.

Coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Paul brings over 35 years of global medical technology management experience to SV.

He joined SV in 2009 as a Venture Partner and in 2011 was made a Partner. Paul was promoted to Managing Partner & COO in 2014 and heads our medical device investments.

Prior to SV, Paul built and ran medical device businesses for 29 years before joining SV Health Investors. Most recently he was Chief Operating Officer at Boston Scientific (BSC), an $8 billion medical device leader. During his 15 years at BSC, Paul served as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International. During his tenure, the company grew revenue over 20 times. Paul integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations. Previously, Paul held marketing and general management positions at CR Bard and various marketing roles at Kendall (Medtronic).

Outside of SV, Paul serves on the board of Edwards Lifesciences Corporation and the Medical Device Manufacturers Association, and is Chairman of the Innovation Growth Board at the Mass General Brigham health system. In addition, Paul serves on the board of Vibrato Medical, Inc. as a Director. He also served on the board of Advamed for 10 years and is a routine speaker at industry meetings.

Bio coming soon.

Mr. Cohen has served as Chief Executive Officer and member of the board of directors of Axonics since co-founding the company in October 2013. Mr. Cohen is an accredited public company director with over 40 years of experience in leading medical device companies and serving as a board member at a number of private and publicly traded life science companies.

From 2010 to 2012, he served as CEO of Vessix Vascular, a venture capital-backed renal denervation company that was acquired by Boston Scientific in November 2012. Previously, Mr. Cohen spent nearly a decade as Chairman and CEO of Nasdaq-listed Cardiac Science Inc., which was ranked as the fourth fastest growing company in the U.S. in 2004. Mr. Cohen currently serves as a Chairman of the board of BioVentrix Inc., a privately-held transcatheter ventricular restoration company focused on treating congestive heart failure patients.

From May 2006 to July 2021, Mr. Cohen served on the board of directors at BioLife Solutions (Nasdaq: BLFS) a developer and manufacturer of preservation media for regenerative medicine and for the last 8 years served as Chairman. From June 2013 to April 2020, Cohen served as an independent director, chair of the compensation committee and member of the audit and nominating committees of Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI). Mr. Cohen also previously served on the boards of two companies that were successfully sold in 2017: Zurich-based LifeWatch (LIFE.SW), sold to Biotelemetry (Nasdaq: BEAT); and Colorado-based Syncroness, Inc., a privately held contract engineering firm, sold to ALTEN Group, a multibillion-dollar French engineering services company.

Coming soon.

Bio coming soon.

Paul oversees Arboretum’s investment process and leads the firm’s operations. His investments focus on capital-efficient medical device and health IT companies applying novel technologies to underserved markets. He currently serves as a board director for Delphinus Medical Technologies, VYDENCE Medical, Cardiac Dimensions, Allay Therapeutics, and Navv Systems. He led Arboretum’s previous investments in Rethink Autism (acquired by K1) and BioIQ (acquired by LetsGetChecked) and is the former Chief Operating Officer for CerviLenz, where he led the design of the company’s first commercial product from concept to launch. 

Prior to Arboretum, Paul held management positions at Ford Motor Company within product development, manufacturing, and business strategy. He currently serves on the National Advisory Board for the Institute for Healthcare Policy & Innovation at the University of Michigan and is a board director of the Michigan Venture Capital Association. 

Paul earned a BS and MS in Mechanical Engineering from the University of Michigan and an MBA from the Ross School of Business at the University of Michigan.

Business Development, Venture Capital Investment, Mergers & Acquisitions, Sales Management, and Marketing in Medical Device

Specialties: Venture Capital Investment, Mergers and Acquisitions, Market analysis and business plan development for emerging technologies; upstream market strategy, sales management and team leadership; sales team training and development.

Bio coming soon.

Bio coming soon.

Life science and Digital Health Executive with 14+ years based in both US, Germany/ International healthcare experience in global business development /corporate strategy, commercial sales and corporate venture capital for a leading multinational pharmaceutical company.

Chris Eso currently has dual responsibility as Vice President of Business Development & Strategy for both the Structural Heart & Aortic operating unit and the Cardiovascular Portfolio, which includes eight cardiovascular operating units across Medtronic. Chris joined Medtronic in 2011 and has held numerous business development, M&A and strategy positions of increasing responsibility and scope over his tenure at Medtronic in both the businesses and corporate functions.

Previous Roles:

Chris brings more than 25 years of successful professional business and general management experience within the pharmaceutical, biotech and medical device industries, in addition to Medtronic, including Allergan, Watson Pharmaceuticals, Agilent Technologies, and Peregrine Pharmaceuticals. Most of his experience is in a business/corporate development and strategy capacity where he has led more than 50 transactions with consideration of approximately $15 billion, as well as general management capacity running a $50 million revenue-generating wholly-owned subsidiary of a publicly-traded company.

Bio coming soon.

Prior to Ajax, David was an associate at Latham & Watkins LLP, where he advised emerging companies and VC and PE firms on corporate governance issues, equity financings, and M&A transactions.  Before Latham, David served as a judicial law clerk to Chief Justice John Roberts (U.S. Supreme Court), Judge Brett Kavanaugh (U.S. Court of Appeals), and Judge Dabney Friedrich (U.S. District Court), and as a judicial extern to Judge Mark Wallace (U.S. Bankruptcy Court).

David received his J.D. from Harvard Law School, where he served as editor of the Harvard Law Review and graduated first in his class, summa cum laude.  He received his B.S., summa cum laude, from the University of Southern California.  Before law school, David led business development for The Drop Box, a documentary film that has raised over $10 million for children with disabilities through strategic partnerships and worldwide distribution.

Greg Banker is a Partner at Vensana Capital, a venture capital and growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Vensana is actively investing in late development and commercial stage companies across the medtech sector, including medical devices, diagnostics, drug delivery, digital health, and tech-enabled services.

Previously, Greg served as the Director of Strategic Market Development at Vertiflex through its acquisition by Boston Scientific. Prior to Vertiflex, he was an Associate Director in the Life Sciences Practice at Navigant Consulting where he advised a broad spectrum of medical device companies, ranging from venture-backed startups to Fortune 500 corporations, on market development and commercial strategy for novel therapies and emerging technologies.

Bio coming soon.

Health technology executive with extensive experience developing disruptive technology and creating new markets. Passionate about early stage ventures, entrepreneurship, and intrapreneurial efforts that require market analysis, needs assessment, product and business model discovery and definition, corporate strategic planning, and go-to-market execution. 

Bio coming soon.

Bio coming soon.

Coming soon.

Serial life science entrepreneur and innovator dedicated to globally commercializing world changing medical technologies. Leadership experience from early idea stages through global product launches in both private and public companies, with significant domestic and international management experience.

I am Managing Director of Cleveland Clinic Ventures, whose focus is on companies in the medical device, life sciences and digital health sectors.

I have over twenty-five years of experience as an investor, board member, M&A advisor and corporate business development executive for companies and opportunities across healthcare, with particular expertise in medical devices and medical technology.

Bio coming soon.

Siddarth Satish serves as Vice President of Digital Innovation for the Surgical Technologies business at Stryker. Previously, he was the Chief Executive Officer of Gauss Surgical, a venture-backed healthcare AI company acquired by Stryker in 2021. Siddarth founded Gauss in 2011 and served as its Chief Technology Officer until he was appointed CEO in 2015. While at Gauss, he initiated the development of Triton, a computer vision application for monitoring surgical blood loss, and led the company through De Novo clearance from the U.S. Food and Drug Administration (FDA) in 2014 and early market launch. Under Siddarth’s commercial leadership, Triton was widely adopted by US health systems, surpassing 250,000 surgical procedures annually by 2019 and winning regulatory approvals in the EU and Asia Pacific regions. In 2018, Triton received the Apple Design Award, which recognizes the best in design, innovation, and technology on Apple platforms. In his operating roles, Siddarth raised $60 million in venture capital financing and architected the spinoff of several home diagnostics technologies developed by Gauss in response to the COVID-19 pandemic. From 2011 to 2013, Siddarth served as an Entrepreneur-in-Residence at StartX, Stanford University’s Startup Accelerator. Prior to founding Gauss, Siddarth held a SIMdesign fellowship in the Department of Surgery at Stanford University and performed research in computer-aided drug discovery at Gilead Sciences. Siddarth received a B.S. in Chemical Engineering from the University of California, Berkeley, and an M.S. in Bioengineering from the UC Berkeley-UCSF Joint Graduate Group in Bioengineering. He holds over 50 issued or pending patents in the fields of surgery, diagnostics, and computer vision and was named to the Forbes 30 Under 30 list in Healthcare.

Dr. Marengère is responsible for TVM Capital Life Science’s overall investment strategy and global fund operations.

Dr. Marengère joined TVM in 2012 and has 23 years of venture capital experience. He was a key driver of the implementation of the TVM LSI I investment strategy which resulted in a number of investments. He is a Director on the Boards of Emovi Inc.; Acanthas Pharma; Occelaris Pharma; Ixchelsis; PRCL Pharma; Panthera Dental; FAAH Pharma; Kaneq Biosciences; Acer Therapeutics as well as Rapid Micro Biosciences. Luc was on the Board of Colucid Pharma Inc. and Aurka Pharma which were recently sold to Eli Lilly for US $960M and US $575M respectively.

Dr. Marengère brings a significant track record to TVM given his long standing experience as  a Venture Capitalist. Very notable deals during Luc‘s previous tenure as Managing Partner at VG Partners include Cytochroma Inc. (sold to Opko for US$ 400M); VisualSonics (sold to Sonosite for US $75M) and CITA Neuropharma (sold to Vernalis Plc for US$ 85M). Prior to joining VG Partners, Luc focused on making venture investments in the life science sector while at La Caisse De Depot‘s venture capital group SOFINOV as well as MDS Capital and MedTech Partners.

Bio coming soon.

Bio coming soon.

Sean is interested in investing at the intersection of devices, life sciences, and software. He combines more than 15 years of strategic, technical, policy, and M&A experience to create value for companies, drawing from past roles at Philips, U.S. FDA CDRH, Boston Consulting Group, and operating at several health tech startups. Previously as a Partner at Philips Ventures, his investments covered interventional neurovascular and cardiology, patient monitoring, wearables, post-acute rehab, prenatal care, COPD, emergency care, imaging, digital pathology diagnostics, enterprise SaaS, and patient engagement.

Sean received a PhD in Engineering from the University of Cambridge, where he focused on medical device design, specifically the study of fluid dynamics in blood flow and pulmonary drug delivery, and graduated from the Johns Hopkins Biomedical Engineering undergraduate program, where he now serves as an Advisory Board member. Beyond healthcare, Sean is passionate about supporting the development of education access for all.

Bio coming soon.

Auriel August MD is physician, innovator and investor passionate about driving change in healthcare.

He is widely sought after for his strategic insight and knowledge of structuring M&A transactions and currently serves on the boards of several healthcare companies, including Shockwave Medical (NASDAQ: SWAV), Avail Medsystems, RefleXion Medical, Tissium and Neptune Medical.

Bio coming soon.

Bio coming soon.

Experienced executive in Healthcare with operational and financial expertise. Interested in Healthcare ventures and new Technologies. Helping entrepreneurs to establish a business and develop a business model. Coach entrepreneurs on their endevours. Investing in new Healthcare start ups. Creating a superior return for investors by helping the human kind.

Bio coming soon.

CLINICAL TRIALS: Patient-focused strategist with 4 years of experience developing global operational plans. Created real-time recruitment dashboards to track DEI goals for 20+ clinical trials leveraging strategies that ensure >90% trials on track with DEI recruitment.

SCIENTIFIC DISCOVERY: Hypothesis-driven scientist with 7+ years of experience investigating cellular stress pathway impact on immunological innate responses. Published 12 high-impact publications and served as a keynote speaker at ~20 conferences with audiences ranging from 250-8000+.

Bio coming soon.

Jeff Peters is a Venture Partner with OrbiMed Advisors and currently serves as the Founder and Chief Executive Officer of evanesce Medical. Mr. Peters has over 25 years of medical device experience in financial and operating consulting roles in public and private companies. Previously, Mr. Peters was the Chief Executive Officer of Cardialen Inc, a company developing low-energy arrythmia management therapy; Anulex Technologies, a company developing minimally invasive spine therapies; he also served as the Chief Technology Officer of ev3 (now Medtronic). Mr. Peters’ prior financial roles include Portfolio Manager at Black River Asset Management, Entrepreneur in Residence at Foundation Medical, and Equity Analyst at Dain Rauscher Wessels. 

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

As Vice President and Chief Innovation Officer, Dr. Eskandanian leads the strategic and operational management of novel product development at Children’s National, with a focus on translating pediatric innovation to patients and families. She is the Managing Director of Innovation Ventures, the commercialization arm of Children’s National, the Executive Director of the Sheikh Zayed Institute for Pediatric Surgical Innovation, and Principal Investigator of the National Capital Consortium for Pediatric Device Innovation, an FDA-funded initiative. Most recently, Dr. Eskandanian played a critical leadership role in the development of the Children’s National Research and Innovation Campus (opening in second quarter 2021), housing Children’s National Research Institute as well as JLABS @ Washington, DC and Virginia Tech as the initial anchors of the campus. Dr. Eskandanian works with a large network of small and large businesses, nonprofits, and government agencies to maximize the commercial potential of pediatric novel products. Since early 2014, over 160 pediatric medical device companies have been funded and/or received technical expertise through initiatives led by Dr. Eskandanian. Her own innovations are in the market space for decades, used by millions. Dr. Eskandanian is the lead inventor of the first-ever adverse event reporting system, initially deployed in a research academic environment. She has had leadership roles in the development of the first web-based consumer trouble-entry management system for a Fortune 100 company in the telecommunications sector. In her role in academia, she has been instrumental in securing over $100 million in peer-reviewed government funding.

Bio coming soon.

As the VP of Product at Eko, I lead the product innovation and strategy for transforming cardiopulmonary care with AI and cloud computing. With over 20 years of experience in healthcare product leadership, I have launched impactful solutions across services, software, implantable and wearable devices that have improved patient outcomes and user experiences worldwide.

My core competencies include defining and validating user needs, mapping customers' jobs to be done, understanding the value chain, and identifying new opportunities for clinical and business impact. I also have extensive experience in conducting market research, segmentation, and ethnography, developing portfolio strategy, managing product lifecycle, and driving market-aligned scope and risk mitigation. I have directly led the initiation, development, and launch of products and services that have touched over 8 million patient lives in domains such as interventional pulmonology, thoracic surgery, peripheral and endovascular therapies, renal care, and digital health. My mission is to grow the impact of cardiopulmonary screening and intervention on patient lives, globally.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Brett Potts advises business owners, shareholders, corporate boards and investors in matters relating to mergers and acquisitions, corporate development, financial analysis and valuation for NewCap Partners.  Brett has mergers and acquisitions experience across a broad base of industry sectors including:  software, composite materials, aerospace and defense,  manufacturing, horticulture, business-to-business services and training.

Prior to joining NewCap Partners, Brett founded Coast Practical, Inc., a growth and exit consultancy with a portfolio of small business investments, focusing on high growth businesses in Southern California across a variety of sectors.   Brett has held Board of Directors, CEO, CFO and COO roles in several of these portfolio clients and led or otherwise been involved in many M&A and capital raising transactions as a result of this work.

Prior to Coast Practical, Brett led business units within Cintas Corporation (NASDAQ: CTAS), spending five years as a General Manager specializing in turnarounds.  In each of his four key leadership roles, the business units made dramatic rapid progress in profitability, year-on-year growth, safety and customer satisfaction, while reducing employee turnover.  He was regularly involved in strategic advisory on acquisition prospects for the growing Fortune 500 company.

Charles Hamilton is a managing director within the Piper Sandler healthcare group and a senior partner of the medical technology team. Charles advises clients across a full range of investment banking services, including sell-side, buy-side and cross-border M&A, corporate carve-outs, public and private equity and debt financings, capital allocation and defensive advisory. Charles has 20 years of healthcare investment banking and capital markets experience, and has completed over 80 M&A and capital markets transactions on behalf of his medical technology clients at Piper Sandler.

Bio coming soon.

Andrew ElBardissi, M.D., is a Partner on the Medical Technologies team and joined the Firm in 2017. Prior to Deerfield, Dr. ElBardissi was a Principal at Longitude Capital, where he focused on investments in medtech and biotechnology. Before that, he was an Associate in JPMorgan’s healthcare investment banking practice. Dr. ElBardissi received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. He has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has authored over 30 publications in leading peer-reviewed scientific journals and has presented his research at numerous medical and surgical conferences. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University.

Bio coming soon.

Alexander is a Partner at Endeavour Vision, investing in medical technology, digital health and diagnostics companies across multiple therapeutic areas.

Alexander brings more than two decades of business and strategy experience in both medical device and high-technology companies. He currently represents Endeavour Vision on the boards of Kenbi, Relievant MedSystems, Lumeon, Rapid Micro Biosystems (NASDAQ:RPID) and VentureMed, and led the firm’s investments in Gynesonics, Nuvaira and V-Wave. He previously served on the boards of VertiFlex (acquired by Boston Scientific in 2019) and EndoStim. He is a member of the steering committee for PCR Innovators’ Day and serves as both a jury member and expert panelist for the Healthtech Summit.

Prior to joining the Endeavour Vision team, Alexander spent nine years with Biosensors International Group, an interventional cardiology company, where he served as vice president of business development. He previously worked with LogiSpring Ventures, MicroStrategy and McKinsey & Co.

Joshua Eckelberry graduated with honors from East Tennessee State University with a BS in Biochemistry as a Mayme Frazier Scholar and then attended Quillen College of Medicine for two years on the nationally ranked rural health track before diverting to pursue an MBA in Healthcare Administration. While in school he pioneered Quillen's anatomy lab internship where he helped create the school's first digital dissector, served as president of the local American Medical School Association, helped negotiated a hospital staffing contract worth over $1M, and raised over $200K for area non-profit clinics. With his understanding of both the science and business sides of the life science industry, Josh helps translate and negotiate the optimal outcome for patients and the companies. Josh has a lifelong commitment to drive positive impact on the community and the world through leveraged change.

Bio coming soon.

Sascha Berger, PhD, joined the TVM Capital Life Science team in Munich in 2016. He is active in deal flow generation, investment due diligence, deal and exit transactions, investor communication as well as corporate finance aspects of the fund.

Sascha has a strong financial background with almost ten years of professional transaction and strategy experience. He has a track-record of concluding 20 M&A transactions, five of those he led as responsible project manager in his previous role as Senior M&A Manager in a PE backed global corporation. He was a core team member in a successful EUR 2.5bn revenue cross-border merger and successfully coordinated global merger clearance procedures (USA, China, EU, Korea).

Prior to this recent role, Sascha successfully advised multiple renowned clients in corporate finance and strategy projects working as (senior) consultant for PricewaterhouseCoopers and the Boston Consulting Group. He was selected for the global leadership development program in his previous role and was named a global high-potential in PwC.

Sascha studied technology management in Munich, Singapore and Boston and  holds a Master from Munich University of Technology with majors in entrepreneurial finance and chemistry, magna cum laude. In his master thesis he analyzed the specific challenges of biotech VC financing rounds. Later he completed his PhD studies in banking and finance while already working for PwC. He is a regular speaker on corporate finance topics for German universities and business schools.

Strong vision and strategy skills. Good at understanding technology adoption trends. Significant experience in public and private high tech boards. Strong experience in investing at the seed/angel level in technology and life science. Seeking public company board position in a company that is re-thinking its strategy and would benefit from a strong visionary leader. Very experienced in rapidly growing auto safety systems from camera processors to Head-Up displays. More recently, gaining a lot of experience from investing in Life Science start-ups via KYTO. Active in the Band of Angels and the Keiretsu Forum.

Anthony Williams joined HealthQuest in 2019. Before joining HealthQuest, Anthony spent eight years at Globus Medical, Inc. (NYSE: GMED), a multinational medical device company focused on developing products that promote healing in patients suffering from musculoskeletal disorders. He served in a variety of leadership roles during his tenure at Globus and ultimately spent the last 3½ years as President of the company. He currently serves as a board member on portfolio companies ENT Specialty Partners and 83bar, and as an observer for Magnolia, TigerConnect and Trice.

Prior to joining Globus Medical, Anthony was a partner with Wyrick Robbins Yates & Ponton LLP, a law firm based in Raleigh, North Carolina, where he specialized in corporate and transactional work for high growth life sciences companies and their investors, including public and private financings, mergers, acquisitions and other strategic transactions, and corporate governance matters. 

Throughout his career, Anthony has been a frequent speaker to entrepreneurial groups, such as the Durham, NC-based Council for Entrepreneurial Development. He previously served on the board of directors of SEBIO and is currently a mentor to entrepreneurs through the Philadelphia-based Mentor Connect, a program sponsored by Ben Franklin Technology Partners and the Philadelphia Alliance for Capital and Technologies (PACT), and Austin-based Texas Health Catalyst, a collaborative initiative of Dell Medical School and the University of Texas at Austin,  both of which provide much-needed mentoring to inventors and entrepreneurs.

Akhilesh joined MVM in 2019. Prior to joining, he practiced medicine as a resident at Beth Israel Deaconess Medical Center and Signature Healthcare Brockton Hospital. In addition, his research on healthcare systems has led to more than a dozen scientific publications and 50 articles in the popular press, including in The Washington Post and Scientific American.

Akhilesh received an MD at the Stanford School of Medicine and an MBA at the Stanford Graduate School of Business. He also holds an AB magna cum laude with highest honors from Harvard University.

Akhilesh is a member of the board of AccuVein, Inc. and Neurolens, Inc., and represents MVM’s investment in InBrace. He was previously a board observer of Patient Connect Ltd (acquired by Clarivate).

Venture capitalist currently investing in medical devices that improve surgical outcomes. Seasoned finance & corporate development professional with broad international exposure in N. America, Europe & Asia. Have closed 28 investments totaling $450M, 5 divestments ($440M), 15 rounds of financing ($700M). Led strategy, M&A, restructuring, integration and IPO preparation efforts, as well as implementation of new financial systems, cost reduction, internal control/compliance and working capital initiatives in a number of different environments incl. MNCs, start-up, publicly listed and privately held.

Edward Hanlon joined Gilde Healthcare in 2020 in the Cambridge office and focuses on Healthtech.

Prior to joining Gilde, Edward worked in advisory for Health Advances, a consulting firm operating across healthcare sectors in medical devices, biopharma, health technology, and diagnostics. He has broad experience in commercial strategy and M&A due diligence, advising a range of clients including late-stage start-ups, multinational corporations, and financial investors. Since joining the Gilde Healthcare, Eddie has contributed to several investments, including Eargo, Spire Health, and Nalu Medical.

Tamir is tasked with leading supporting the investment process in Israel and Europe, working closely with JJDC and J&J stakeholders on developing and executing investment transactions across J&J’s sectors. Tamir's main focus is Medical Devices, Digital Technologies and Consumer products.

Bio coming soon.

I invest in commercial-stage healthcare and life science companies in the following subsectors: medical technology/devices, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and research tools.

Ideal target investment opportunities address significant unmet needs with large addressable markets, including medical conditions for which there are no adequate treatments, therapies for which existing treatments are too expensive, or diseases that lack accurate diagnostic capability, along with the various businesses and products that enable these solutions.

Greg is a senior private equity investment professional. Expert in investment due diligence, equity and debt financing structures, private capital formation and has extensive M&A and IPO exit experience. Greg is a proven portfolio strategy executive and director on the company boards he serves.

Kevin is the Founder and Managing Partner of the McGeever family office, which focuses on achieving the financial and philanthropic goals of the family. McGeever’s investment portfolio places an emphasis on Healthcare, but also includes Technology, Energy and Real Estate.

To support the success of McGeever’s investments, Kevin founded SalesForce4Hire, a company that provides strategic commercialization solutions for medical device, diagnostics, biopharma and information technology companies and their investors. SalesForce4Hire has played an instrumental role in the successful implementation of customized sales solutions with Fortune 500 and startup companies.

Kevin is also an active angel investor who enjoys working closely with CEOs and leadership teams on strategic partnering and commercialization activities. He has held several executive-level and board-level positions, including Audit and Compensation Committee Member, Committee Chairman, Board Chairman and is an advisory board member of the Cameron School of Business at the University of North Carolina Wilmington.

John leads the healthcare division of WFSC which is focused on direct equity and debt investments in companies across all subsectors of the healthcare industry. John has been a venture capital and private equity investor for more than 24 years and has participated in the founding, building, and financing of companies, ranging from startups to established industry leaders in a wide array of healthcare sectors. John started his career as an investment banker covering the healthcare industry.  John earned a BS with high honors from the University of Colorado at Colorado Springs and an MBA from Harvard Business School.  John is based in San Francisco, California.

Bio coming soon.

Experienced Private Equity / Corporate Development / Venture Capital / Strategy professional with track record of:

- Collaborate with operating businesses to develop strategic themes and gap analyses.
- Evaluate investment opportunities and execute transactions including M&As, buyouts, as well as growth equity / venture investments.
- Work with portfolio companies' management teams and boards on variety of operational and strategic issues. Serve on portfolio company boards.
- Support CEO/CFO/Executive Committee/Board on strategic projects / analyses, as well as leading workstreams critical to managing company's financial health, capital allocation and M&A prioritization.

Global strategic leadership within the health care and MedTech industries with a focus on delivering innovative business models, software and solutions that advance patient care & drive profitable growth.

Bio coming soon.

Over 20 years in corporate legal environments with experience in legal issues unique to the health care field. Valued leader with demonstrated ability to advise and guide senior leadership on complex business and legal issues.

Yosuke Matsubara is a Business Development and Licensing Manager at Teijin Pharma, a Tokyo-based company that operates in both pharmaceuticals and medical devices. With over 10 years of experience in drug development at Teijin Pharma, Yosuke's expertise lies in clinical trials, negotiating with regulatory agencies for approval, and project management.

Yosuke is responsible for licensing-in both medical devices and drugs, focused on exploring potential collaborations and partnerships with startups in the medical device and drug spaces. Teijin Pharma's medical device business is limited to home-use devices, and its businesses are limited to the Japanese market. Many of the company's available products in Japan are from overseas, and licensing-in is an important activity.

Yosuke earned his Ph.D. degree in medical science before joining Teijin Pharma in 2008. Prior to joining Teijin Pharma's medical device business in 2021, he gained extensive experience in drug development.

With over 25 years of experience in the Medtech sector, I am a results-oriented executive who leads with vision, passion, and purpose. I have a proven track record of building and motivating diverse, high-performing teams to drive worldwide growth and market share gain through customer-driven strategies and focused execution.

As the Vice President of Marketing at FUJIFILM Sonosite, I am responsible for delivering the global marketing strategy, product management, education and downstream marketing for the market-leading $360M point-of-care ultrasound business. I leverage my core competencies in strategic planning, merger and acquisition, diversity, equity and inclusion, branding and communications, new product development and launch, market development, product and portfolio management, team development and leadership, and digital marketing and demand generation to create value for our customers, partners, and stakeholders. I am committed to advancing the field of point-of-care ultrasound and improving the quality of care for patients around the world.

Bio coming soon.

Nirav Dalal leads the Global Data Science and Analytics function at Abbott medical devices. Nirav is interested in methods and tools to improve healthcare and create value using “Big Data” and machine learning. He has published more than fifty peer-reviewed journal articles, conference abstracts and US patents. 

He is a frequent speaker on medical devices, real-world evidence, digital health, health economics and data science. His selected past speaking engagements include talks at FDA, NMPA, AdvaMed, Big Data in Healthcare, American Chamber of Commerce, Medical Design & Manufacturing, and Global Cardiovascular Clinical Trialists Forum.

2008 - Jan 2017: Operating Partner specializing in medical technology venture capital investments at Sanderling Ventures & active CEO/CTO of several portfolio companies (Member of investment committee)

Currently:
- Advisor to J&J Neurovascular (former CEO of Pulsar Vascular) , a neurovascular device company w special vascular implants to treat bifurcation cerebral aneurysms.
Acquired by Codman Neurovascular J & J Dec 2016
- Executive Chairman for Dynatherm Inc, a normathermia device to assure patient temp management during surgery - "plus"
- Former CEO for Theregen Corp, a cell delivery patch device to treat angina patients, w potential for CHF patients. ( In Clinical trials )

Medical Device product design and development for Guidant, Boston Scientific, and small start-ups...mostly minimally invasive disposable technologies.
- 75 patents in medical devices
- Invented, developed and launched numerous products .
e,g Guidant BMW guidewire, MultiLink Stent, Target Therapeutic coils and stents, vascular recontruction devices

After completing an MBA at the Yale School of Management, New Haven, CT, in May 2014, I decided to leave the practice of medicine. I am fortunate to be able to utilize my knowledge of business and healthcare in my current role with Stryker Spine in Business Development. Prior to accepting a position with Stryker, I worked as a spine surgeon at the Montefiore Medical Center, Bronx, NY and held the title of Assistant Professor of Orthopaedic Surgery at the Albert Einstein College of Medicine, Bronx, NY. I am a board-certified orthopaedic surgeon with fellowship training in adult and pediatric spinal surgery.

Bio coming soon.

RC Capital (formerly River Cities Capital Funds) is a Healthcare focused growth equity fund, currently investing out of our seventh fund. We look to invest in leading companies with $5M - $30M of revenue throughout the country. Specific areas of interest include medical devices, healthcare services, and healthcare IT.

I am fortunate to have worked alongside some amazing entrepreneurs over the last 18 years as an investor to help build some great businesses.

Specialties: Strategic visioning, Industry Analysis, Due Diligence, Valued added research. The role of an investor is to be able to able to look around the corner and identify areas for growth while avoiding the potholes that slow value creation. We focus on efficiently "bending the growth curve" through introductions to potential talent, customers, and partners and then leveraging that growth to optimize the long term value.

Experienced global commercial leader and molecular biologist with expertise in IVD, Medtech, clinical research, regulatory compliance, product development, market insights, infectious disease, oncology, digital health, and family office management.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

In January 2018 I joined imec.xpand as a Partner. In the mean time we committed our 1st fund of 117 mio EUR to a portfolio of 15 startups and currently raising imec.xpand Fund II which currently stands at 220 mio EUR (actively investing). Imec.xpand is an early stage and growth VC investor with a game-changing approach to turn hardware driven nanotechnology innovation into successful global companies. The fund is independently managed by a team of entrepreneurs, seasoned venture capitalists and business experts, and is targeting ambitious tech start-ups that meet all the criteria to become a successful, scalable ventures with the potential to change the world, and where imec knowledge, expertise and infrastructure can play a determining role in their success. Imec is the world-leading R&D and innovation hub in nano-electronics and digital technologies based in Leuven, Belgium. For more information about imec.xpand, please visit www.imecxpand.com.

From 2009 until 2017 Frank was a Partner at Capricorn Venture Partners where he was involved with investments in the health care field (diagnostics, therapeutics, medical devices and digital health-tech) for the Capricorn Health-tech Fund, the Capricorn ICT Fund and the Quest for Growth Fund. Main responsibility was building and managing the portfolio of the Capricorn Health-tech Fund through deal sourcing and active board memberships.

Previously, Frank was a executive investment manager within the life science venture capital team at Gimv (Antwerp, Belgium) and a senior scientific advisor within IWT, a research fund organization in Brussels. Prior to Gimv and IWT Frank worked at the Faculty of Medicine, University of Leuven as a PhD and postdoctoral researcher. Frank is trained as an industrial engineer in chemistry/biochemistry and obtained a Master Degree as well as a PhD in Medical Sciences at the University of Leuven, Belgium.

Throughout his nearly 25 years of making active venture capital investments Frank collected a vast experience in building early stage tech companies towards a successful exit through trade sale/IPO.

Bio coming soon.

Steven M. Gottlieb, M.D., is a physician executive and healthcare serial entrepreneur who seeks innovative companies in which he can invest, add value and accelerate growth. Dr. Gottlieb has more than 30 years of senior leadership experience in the healthcare industry, and has founded, managed, funded, grown and exited several successful healthcare companies.

Dr. Gottlieb served as CEO of TeamHealth Anesthesia, the national anesthesia division of TeamHealth (NYSE: TMH)—one of the largest providers of outsourced physician staffing solutions for hospitals in the US.

He was co-founder, CEO and president of Anesthetix Management—a leading national provider of anesthesiology and pain management service solutions to hospitals and surgery centers. Dr. Gottlieb successfully led the company through its growth and development, including a private equity investment by Summit Partners in 2006, its acquisition by TeamHealth (a Blackstone company) in 2009, and an IPO in 2010.

Dr. Gottlieb founded and led an independent physicians' association, a medical billing company, and a healthcare recruiting and staffing company.

Investor at 1315 Capital, a healthcare focused growth equity fund investing in commercial-stage companies with $5-$50 million of revenue.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Kwame Ulmer is a venture partner at Wavemaker Three-Sixty Health - the leading Southern-California based, early stage venture capital firm (Seed and Series A) focused on the healthcare industry. He leads the medtech practice and participates in all aspects of fund management (e.g. deal sourcing, diligence, negotiation and advising portfolio company management teams).

Kwame brings twenty years of experience evaluating medical technologies in the government and private sector, and serving in senior operating roles at medical device companies. He has personally evaluated more than 1,000 medical technologies in his career. Kwame spent 12 years at the U.S. Food and Drug Administration (FDA) in progressive leadership roles, including Deputy Director and Branch Chief. He also served as Vice President, Regulatory Affairs and Quality Assurance at Implant Direct, a Danaher Corporation operating company.

Kwame serves on the board of the University of Virginia Licensing and Ventures Group and the California Life Sciences. He is also a lecturer and researcher in MedTech Innovation at the University of California, Los Angeles. Kwame founded MedTech Color, a nonprofit with a mission to advance the representation of persons of color in the medical device industry. He earned his B.S. in Physics from Lincoln University, and has two Masters degrees from the University of Virginia, in Materials Engineering and Business Administration.

With over 20 years of experience in research, innovation, and commercialization, Ryan is a scientist-turned-health-innovation-expert at the forefront of biomedical research, commercialization, and transformation.

As the leader of a talented team at the Innovation Lab, a for-profit incubator owned by six non-profit health systems, Ryan directs the innovation and commercialization program that turns ideas into products, taking them from concept all the way to market. Together, Ryan and his team collaborate with over 200,000 medical professionals and a diverse ecosystem of industry, venture, and academic partners to bring innovative products and solutions to patients at scale.

Ryan's achievements include millions of dollars in closed deals, strategic partnerships, grants, and fellowships, along with many guest speaking engagements and peer-reviewed publications. With a unique blend of health, tech, and business mindsets, Ryan translates unmet needs into implemented solutions and advises organizations and their leaders on innovation and transformation.

Ryan earned his Ph.D. in immunology from the University of Minnesota, a BS in biochemistry from Cal Poly San Luis Obispo, and MBA from the University of Southern California. He is passionate about guiding and empowering frontline medical professionals to develop innovative products and services that improve the quality of healthcare for all.

Bio coming soon.

Bio coming soon.

Experienced Regional Vice President with a demonstrated history of working in the medical device industry. Strong business development professional skilled in Negotiation, Vascular, Medical Devices, Capital Equipment, and Sales Management.

With over 30 years experience in medical sales, marketing and product  development, John leads the Medtech Innovation and Business Development at Cambridge Consultants. John has led various projects involving leading edge medical devices, creating solutions for our client’s needs. John is also the commercial lead for Cambridge’s Smart Implant Development team.

Prior to this, John was the OEM Director for Baxter and Cardinal Healthcare, creating new business ventures that included three manufacturing facilities, various outsource allegiances (domestic and international) and developing intellectual property.

Glenn leads Deloitte LLP's Medical Technology practice with more than 25 years of experience in medical technology, biotech, and specialty pharmaceuticals. He helps clients grow through organic and inorganic means by entering new geographic markets, and expanding into new product/service areas. Glenn also helps clients improve brand/commercial effectiveness by articulating product economic value, applying innovative pricing, updating the commercial model, and rationalizing distribution networks.

Maite is currently doing a graduate program at Harvard University, in Corporate Innovation and Sustainability, holds a bachelor's degree in International Business from Universitat Pompeu Fabra (UPF) and the University of Florida (Warrington College of Business), and a master's degree in Digital Marketing by ISDI.

Venture Builder in the healthtech industry, bringing early stage innovation to the patient by founding startups. Background in genetic engineering, cell and molecular biology. Experience in strategy consulting and venture capital. Passionate about innovation, sustainable impact, tech solutions.

Pieter Wijffels is a venture partner at NLC. Prior to this, they were the head of marketing at TPV and Philips. Pieter has also worked as a project manager at Boer & Croon and as an intern at Sara Lee.

DR. STUART HART is the corporate vice president and chief medical officer. He is responsible for Integra’s worldwide clinical development activities, including clinical research, clinical trial operations and medical affairs. Dr. Hart is also responsible for scientific and medical support, medical safety and R&D innovation.

Prior to joining Integra in January 2023, Dr. Hart served as vice president, Medical Affairs for Urology and Critical Care at Becton Dickinson (BD). Before joining BD, he served as a senior medical director for the Surgical Innovations business at Medtronic. Before joining the medical device industry, Dr. Hart spent much of his career working as an academic physician at Emory University and the University of South Florida (USF). He also served as the director of the Tampa Bay Research and Innovation Center and was the chief medical officer for innovation and director of the Center for the Advancement of Minimally-Invasive Pelvic Surgery at the USF Health Center for Advanced Medical Learning and Simulation.

Dr. Hart is board certified in obstetrics and gynecology with a sub-specialty board certification in female pelvic medicine and reconstructive surgery. He is a fellow of the American College of Obstetricians and Gynecologists and the American College of Surgeons.

Dr. Hart received his medical degree from the University of Maryland and completed his training at Emory University and associated hospitals in Atlanta, Ga. He has an MBA from the Massachusetts Institute of Technology (MIT) Sloan School of Management, a master’s degree in entrepreneurship in applied technologies from the USF Muma College of Business, and a graduate certificate in regulatory affairs in medical devices from the USF College of Engineering. He also completed the Managing Innovation executive education program through the Stanford University Byers Center for Biodesign.

Dr. Hart has published more than 40 peer-reviewed journal articles, filed 15 patents, and has won numerous awards for innovation, research studies and teaching.

Dr. Azin Parhizgar served as Chief Executive Officer, President and Board Member at Claret Medical. She is an experienced and successful medical device industry executive and entrepreneur. Prior to Claret Medical, she served as the Chief Operating Officer of Conor Medsystems which led to the acquisition of the company by Johnson & Johnson, Inc. in 2007. She spent one year post-merger with Johnson & Johnson for full integration of the companies. Between 1996-2000 she held the position of Executive Vice President for Arterial Vascular Engineering, which was acquired by Medtronic. She spent two years at Medtronic post-merger in increasing roles of responsibility leading to her role as Executive Vice President of Emerging Ventures and New Technologies. Dr. Parhizgar has served as an advisor to emerging medical device technology companies including several Board of Directors and Scientific Advisory Board positions. Dr. Parhizgar received both her Ph.D. in Cell, Gene and Tissue Engineering and her M.Sc. in Biomechanical Engineering and Artificial Organ Design from Brown University.

Bio coming soon.

Suraj Mudichintala is a senior associate at APVC in Santa Cruz, CA. He represents APVC on the Boards of Alpheus Medical, Axon Therapies and Onc.ai. He was previously an investor at Arboretum Ventures, where he served as a Board observer at Allay Therapeutics, Avation Medical, Francis Medical, Health Scholars, Koya Medical, and RareCyte. Prior to investing, Suraj was an associate with L.E.K. Consulting, a global strategy consulting firm. While at L.E.K., Suraj completed ~20 engagements predominantly for life sciences and private equity clients.

Suraj graduated cum laude with a B.S. in Finance and Analytics from Boston College. Suraj previously served on the Michigan Translational Research and Commercialization (MTRAC) Oversight Committee for Medical Devices, where he provided guidance to Michigan higher education researchers on transitioning their early stage products to the private sector for commercialization.

Omid is currently a Managing Director at Anthro Ventures, investing across medical devices, diagnostics, digital health and healthcare services. Previously, he worked as an Investment Principal at MVM Life Science Partners LLP and Becton Dickinson as Director of Strategy and Business Development. Prior to that, Omid was a management consultant at Monitor Deloitte in the Life Sciences and Healthcare team. Omid holds a Masters in Bioengineering from the Johns Hopkins University and a Bachelors in Biomedical Engineering from the University of Virginia. He also received a Fulbright Award to conduct research on access to healthcare in the Middle East.

Bio coming soon,

Bio coming soon.

Luke Düster is a member of CRG’s Founders Group, serves as Chief Investment Officer, ESG Champion and a Member of CRG’s Investment Committee and ESG Committee. He is also responsible for portfolio management and portfolio company exits.  Mr. Düster also serves on the board of directors of several CRG portfolio companies, both as a director and as an observer, and serves portfolio company senior management teams as an advisor on financial, strategic and operational initiatives.  He has led investments in companies such as Neotract, Nevro, Omeros, BioDelivery Sciences, Strongbridge Biopharma, Silk Road Medical, NanoString Technologies and many others.

Prior to CRG, Mr. Düster was an investment banker at Harris Williams & Co., where he advised private equity and corporate clients across a broad range of M&A assignments.  Mr. Düster also held investment banking roles at the Wallach Company, a regional investment banking boutique, and at the Nord Companies, a healthcare advisory firm.

Mr. Düster received a bachelor’s degree from the University of Colorado at Boulder in 1997, where he graduated summa cum laude. He received an M.B.A with honors from the Wharton School at the University of Pennsylvania in 2004. 

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon,

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

David broadly supports the Broadview investment team in its day-to-day operations, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement.

Prior to joining Broadview, David was a Senior Associate at Locust Walk, a global life sciences transaction firm, where he led engagements for biopharma and medtech clients guiding corporate development strategy and supporting sell-side, buy-side, and financing deal execution. Previously, David was a consultant a ClearView Healthcare Partners, a premier life science strategy consulting firm, where he supported completion of high-impact strategy projects for a broad range of industry clients across all aspects of the product lifecycle, including new product planning, R&D, commercial, medical affairs, market access, and lifecycle management.

David earned a PhD in Biomedical Engineering from the University of South Carolina, where his research focused on vascular grafting. His research projects covered a wide range of vascular mechanics, hemodynamics, and tissue engineering, with a specific focus on understanding and improving remodeling of coronary artery bypass grafts. David also holds a BS in Biomedical Engineering from the University of South Carolina with honors from the South Carolina Honors College.

David serves on the Board of Directors for Puzzle Medical Devices.

Bio comings soon.

Bio coming soon.

Bio coming soon.

Ariana Ognibene is a vice president within the corporate relationship management group at SVB, based in San Diego. In this role she focuses on fostering relationships with corporate development, investment and innovation teams at the largest and most influential corporations in the Life Sciences and Healthcare ecosystem and helping these corporations and SVB clients maximize their success and achieve their unique goals.

Ariana originally joined Silicon Valley Bank in 2015. Her SVB career began in her hometown of Boston, where she focused on supporting venture-backed biotechnology and diagnostics companies in the Northeast. In 2018, she migrated to San Diego, where she supported and advised venture-backed medical device and health-tech companies in the Southwest US. Ariana most recently transitioned to lead the life science and healthcare efforts for the corporate venture team in October of 2021.

Ariana is a member of Biocom’s Medical Device Committee and previously worked with Springboard Enterprises, an organization that supports promising high-growth, woman-led companies. Ariana holds a bachelor’s degree in economics from the College of the Holy Cross in Worcester, Massachusetts. Her studies also included a semester at University College Dublin.

Ariana comes from a family of three sisters (she’s the eldest) and two dogs, all of whom still live in the Boston area. An avid dancer for 15 years, she enjoys various genres of the art form. Her free time finds her running, hiking and reading, as well as satisfying her deep love for Italian food.

Bio coming soon.

With over 10 years of experience as a physician, operator, and entrepreneur, I am passionate about using innovative technology to improve healthcare. I have led and contributed to the growth and success of several start-ups in the fields of virtual reality, surgical simulation, and digital health, leveraging my clinical and business acumen, strategic partnerships, and product management skills.

Currently, I am the Head of Business Development and Product Strategy at clint, a company that has patented technology to significantly improve clinical trial design efficiency, effectively recruit diverse trial participants, and close care gaps at the point of care. I drive partnerships and product strategy for our AI platform, which empowers researchers, clinicians, and patients with data-driven insights and solutions. I am always looking for new ways to innovate, exploring opportunities to collaborate and make a positive impact on the healthcare industry.

Rachna is an Outcomes-Based Leader with experience in Venture Capital, Healthcare marketing, Supply Chain, Disruptive Technology Management, External Manufacturing and R&D for big corporations and start-ups. Her career spans across USA, Europe and Asia, and companies like Philips, Handshake Solutions  and Johnson & Johnson. 

Some key accomplishments include successfully managing a network of external manufacturers with P&L of $350 Million, Global Commercial Launch for groundbreaking depression/suicidal drugs and leading a technology startup in the bay area for three years.

Dr. Deng Mao is an Investment Manager at Yonjin Venture, specializing in the Medtech industry. Prior to joining Yonjin in 2021, he worked as a neuroimaging physicist, bridging the gap between physics, medicine, and neuroscience. His extensive experience includes various roles at Philips healthcare, where he served as a development engineer and the clinical scientist for Johns Hopkins and National Institute of Health.Dr. Mao earned his Bachelor of Science in Pharmacy from Tianjin University before pursuing his PhD in Biophysics at the University of Texas Southwestern Medical Center and Johns Hopkins Medicine.

Bio coming soon.

Matthew's professional experiences include work in business development and M&A, corporate finance, valuation and modeling, market strategy, tax strategy and planning, and equity research.

Entrepreneurial venture capitalist with global investment experience across a range of industry sectors including healthtech, medtech, consumer healthcare, foodtech and life sciences.

Responsible for managing existing IGT investment portfolio, including board of director seats, and for executing new investments in collaboration with IGT business development colleagues.

Bhavesh joined Truffle Capital in 2023 as an Operating Partner, specialising in Life Sciences Business Development. Prior to joining he worked for 18 years in the MedTech sector at Tyco Healthcare, Covidien, then transitioning to Medtronic after its merger in 2014. He held various positions of increasing responsibility in sales & marketing, leading regional and global teams, before being appointed to the Regional Vice President UK and Ireland. He is an expert in the surgical devices sector. Bhavesh Barot holds a BSc in Business and IT from Leeds Beckett University.

Bio coming soon.

Bio coming soon.

Coming soon.

Coming soon.

Mr. Josh Berg is an experienced healthcare investment professional with over 26 years of capital markets, investment banking, institutional investor relations and investment management expertise. Mr. Berg is well-versed and skilled at identifying value at all stages of a corporate life cycle and specializes in strategically building institutional shareholder bases for multinational organizations. Mr. Berg’s institutional investor relationships collectively manage more than $300 billion in equity value. Prior to founding Berg Capital Markets, LLC, Mr. Berg developed expertise in institutional equities with bulge bracket and boutique healthcare centric investment banks including Leerink Partners, Wells Fargo Securities, and Pacific Growth Equities. Previous to Mr. Berg’s 11 years of investment banking experience, he facilitated the raise of over $2.0 billion in equity securities for Jurika & Voyles, LP, a value-based institutional equity investment management firm based in Oakland, California.

Through Berg Capital Markets, Mr. Berg and his colleagues successfully deliver a robust, full-service capital markets solution for both public and private Healthcare and Energy companies.
Mr. Berg graduated with a Bachelor of Arts degree in Economics from the University of California at Santa Cruz. Mr. Berg currently lives in San Diego, California, and enjoys reading, traveling, working, cooking, working out, running, investing, and spending time with his children.

Bio coming soon.

Virginia is an accomplished innovation executive with experience spanning Fortune 500 companies to start-ups. She is focused on accelerating disruptive, early stage innovation in healthcare. She works collaboratively, fostering partnerships to access external innovation, as well as to drive internal innovation by setting and aligning strategy, inspiring team and addressing internal barriers to innovation. She believes in the importance of customer- and patient-centric innovation, and to that end, looks for opportunities to be immersed with clinicians in hospital and other healthcare settings.

She has achieved outstanding results, across a spectrum of R&D leadership roles, resulting in launch of clinically impactful medical device products in the orthopaedic, cardiology, ENT and neurology spaces. She is an accomplished scientist, having authored numerous peer reviewed publications and been a frequent presenter at global healthcare conferences. She is a Fellow of the American Institute of Medical and Biological Engineering, the prestigious honorary society for Medtech Engineers.

Virginia also has significant management experience, having managed a variety of technical teams and projects with significant annual budgetary responsibility. She is sought after for her professional guidance and serves on several Advisory Boards.

Rob Cripe is the Chief Commercial Operations Officer at MicroPort Orthopedics Inc. He joined MicroPort in November 2021 and is responsible for leading the development and execution of our global commercial strategy, and integrating our commercial operations globally. Prior to joining MicroPort, Mr. Cripe was at Integrated Endoscopy where he served as Chief Commercial Officer, and brings with him over thirty years of global experience as a leader in the medical device industry, with significant responsibility in large joints, hip, and knee sales, marketing, product development, and clinical functions. Mr. Cripe’s extensive career includes leadership of technology-focused product strategy, at both established companies and commercial start-up ventures.

Kristin Machacek Leary joined MicroVention in 2022. She is a seasoned global human resources executive with over 30 years of business experience. She has worked extensively across the globe to transform companies to the next stage of growth, develop associates at every level, and create high-performing cultures.

Prior to joining MicroVention, Kristin has worked in medical device (Boston Scientific & Alphatec Spine), biopharmaceutical (Quintiles/IQVIA), technology (Hewlett-Packard, Hitachi Vantara & Bullhorn) and renewable energy (EDF-Renewables North America) in senior leadership and executive positions.

Kristin has a Bachelor of Arts in Organizational Communications and English from Concordia College, Moorhead, Minnesota.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Carsten Schroeder joined MicroVention as President and CEO in November of 2020. Mr. Schroeder has more than 25 years of senior executive experience across pharmaceuticals, medical devices, and in-vitro diagnostics. Prior to MicroVention, he was President and CEO of Grifols Diagnostic Solutions, (joining Grifols through the acquisition of Novartis Diagnostics). He was also the President of the Diagnostic Business Unit and the Site Head for Novartis in Emeryville, CA. Before Novartis, he held various Vice President positions at Boston Scientific for nine years and was based in France, Germany, and the United States. During this time, he was responsible for the neurovascular business. Mr. Schroeder speaks several languages and has lived in over 10 countries throughout his career.

Mr. Schroeder earned his Bachelor of Arts in Economics from the University of Cologne in Germany and a Master of Business from the European School of Management in Paris (ESCP)

Bio coming soon.

Bio coming soon.

Bio coming soon.

Nir joined Business Development’s Mayo Clinic Ventures division in 2022 as a technology development manager. He is responsible for facilitating the development and commercialization of technologies from Mayo Clinic’s Department of Surgery by working with internal stakeholders, external companies, entrepreneurs and investors.

Prior to joining Mayo, Nir was CEO of Trendlines Innovation Labs (TIL), which focuses on in-house and collaborative invention and investment opportunities in the life science space. Prior to his appointment as CEO, he served as TIL’s VP Business Development. Before Trendlines, he was director of commercial development in Europe at INSIGHTEC Ltd., a global MR-guided focused ultrasound surgery company.

Nir holds a BSc in engineering from La Sapienza University of Rome.

Bio coming soon.

Bio coming soon.

Coming soon.

Coming soon.

Tiffany joined NEA in 2020 and predominantly invests in Life Sciences, with a strong focus in medical devices, healthtech, and innovations at the intersection of technology and medicine. Previously, Tiffany held roles at Kaiser Permanente Ventures and L.E.K. Consulting. She has also collaborated on research leveraging brain organoid and synthetic biology models to interrogate Alzheimer’s disease. Tiffany received a BA in Business Economic Theory from UCLA and an MBA from Harvard Business School.

Coming soon.

Coming soon.

Rahul joined Technology Holdings in 2011. He has an MBA in Finance and a degree in Computer Science Engineering.

Rahul’s experience spans technology and investment banking, having previously worked at Tata Consultancy Services, Avendus Capital and Corporate Finance Advisors. Outside of work, you can find Rahul spending time with his 8-year-old son. He also enjoys travelling and counts Greece and Switzerland among his favourite destinations.

Clay joined OrbiMed in 2021 and is a Vice President focused on medical technology and other non-therapeutics areas of venture-stage investing. Prior to joining OrbiMed, Clay was a Vice President on the medical technology Equity Research team at BofA Securities. Prior to Equity Research, Clay was an Investment Banking Associate in the healthcare group at BofA Securities. Previously, Clay also worked in management consulting with Accenture Strategy as part of the Operations practice. Clay received a B.Sc. from Vanderbilt University and his M.B.A from Emory University’s Goizueta Business School.   

Andrew joined us in 2023, bringing with him a wealth of experience in the medical devices sector, with expertise in device development, clinical and regulatory strategy, fund-raising, strategic business development, and team leadership.

As a Venture Partner, Andrew investigates global medical device investment opportunities across the Sofinnova Partners platform of strategies. He is currently on the board of May Health and SafeHeal, two companies in the portfolio of Sofinnova's medtech incubator strategy, MD Start.

"I share Sofinnova’s passion for finding, nurturing and bringing new medical device therapies to patients," Weiss said when he was appointed Venture Partner." Having worked both informally and as a portfolio company CEO with Sofinnova for the past 20 years, I know that they have the best team, and are the gold-standard medical device venture group."

In 2013, Andrew was brought in as CEO to lead ReCor Medical, a company founded in 2009 by Mano Iyer, then an entrepreneur in residence at Sofinnova and now a partner in the Sofinnova medtech acceleration team. Mr. Weiss led ReCor, a pioneer in the use of ultrasound renal denervation to treat hypertension, as it scaled up to 175 employees, went through its clinical trials and was purchased by Otsuka Medical Devices in 2018. Sofinnova Partners was the sole VC investor in ReCor at the time of the sale. Andrew stayed at the combined company until 2023, the year ReCor received FDA approval for its Renal Denervation System.

Before he took the reins at ReCor, Andrew held leadership roles including President & CEO of Vital Images (acquired by Toshiba), VP & General Manager of the Medtronic Surgical Navigation Systems and Neurological businesses, and President & CEO of CoAxia, which was sold to Zoll Medical.

Andrew has also been an advisor to and board member of a number of medical device companies in the US, Europe and Israel.

He is a graduate of the Massachusetts Institute of Technology with a degree in mechanical and electrical engineering and has an MBA from the Columbia University Graduate School of Business

With 16 years in global leadership roles within life sciences, I’ve built a proven record in C-suite, top executive and board level searches. My clients represent every aspect of the industry from large multinationals to private equity and VC firms and I’ve worked with them all in a spirit of genuine partnership.

I was formally a board level director with a leading international executive search consultancy, where I developed a reputation as a specialist and industry thought leader in medical devices, medtech and diagnostics. I’ve delivered results across all geographies and senior roles including some of the most technically demanding and hard to fill positions.

Before moving into executive search I worked as a senior executive leading the commercial operations of a US medical device company, Alveolus Inc. I led the business from start-up to product launch over three years, culminating in a successful trade sale.

Prior to my career in healthcare, I was a professional sportsman, representing an England XV and the Barbarians at rugby union. The successful transition from professional rugby player to business leader has made use of many common skills and disciplines. Both professional sport and executive search demand a capacity to deal with significant individual and team pressures, requiring self-discipline and sacrifice combined with a desire to learn and adapt.

I offer a unique blend of life experiences gained through such a varied and highly successful career.

Stefan joined TVM Life Science in 2000 and has been the CFO since 2012.

Stefan holds overall advisory responsibility for the finance operations of the firm’s offices in Europe and North America and for TVM’s life science venture capital funds.

Furthermore, he is responsible for fund administration, investor relations, structuring and negotiating international fund raisings, as well as all corporate finance related aspects of the portfolio. He is in charge of compliance, governance and IT at TVM.

Stefan Fischer is a board member of Myosotis GmbH, Berlin.

Stefan has more than 23 years of venture capital experience. He has been responsible for the corporate finance side of the investment activities for many years and was actively involved in numerous IPOs and trade sales of TVM portfolio companies.

Prior to joining TVM, Stefan was a senior consultant in the corporate finance department of KPMG (Munich), working predominantly on corporate transactions (including M&As and IPOs) and corporate restructuring in national and international projects.

Stefan earned a Master’s Degree in business administration at the University of Passau. His focus was Corporate Finance, Banking and IT. Furthermore, he specialized in Corporate Finance and Business Communication at the Helsinki School of Economics. He is a member of the Working Groups ‘Finance’ at BioDeutschland, and ‘Innovation and Financing’ at the Schmalenbach-Gesellschaft.